April 28, 2017 03:27 PM EDT
Pharma

Take­da gets a po­ten­tial block­buster bonus on $5B Ari­ad deal with FDA’s ap­proval of briga­tinib

John Carroll

Editor & Founder

Take­da is get­ting a big bonus from the FDA to­day for its $5.2 bil­lion buy­out of Ari­ad. The phar­ma com­pa­ny ac­quired the late-stage can­cer drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times